- Home
- ACRS vs ACHV Comparison
ACRS vs ACHV Comparison
Compare ACRS & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- ACHV
- Stock Information
- Founded
- ACRS 2012
- ACHV N/A
- Country
- ACRS United States
- ACHV Canada
- Employees
- ACRS N/A
- ACHV N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ACRS Health Care
- ACHV Health Care
- Exchange
- ACRS Nasdaq
- ACHV Nasdaq
- Market Cap
- ACRS 132.0M
- ACHV 126.9M
- IPO Year
- ACRS 2015
- ACHV N/A
- Fundamental
- Price
- ACRS $2.60
- ACHV $2.87
- Analyst Decision
- ACRS Strong Buy
- ACHV Strong Buy
- Analyst Count
- ACRS 5
- ACHV 5
- Target Price
- ACRS $11.00
- ACHV $14.80
- AVG Volume (30 Days)
- ACRS 956.3K
- ACHV 283.6K
- Earning Date
- ACRS 02-25-2025
- ACHV 11-07-2024
- Dividend Yield
- ACRS N/A
- ACHV N/A
- EPS Growth
- ACRS N/A
- ACHV N/A
- EPS
- ACRS N/A
- ACHV N/A
- Revenue
- ACRS $27,079,000.00
- ACHV N/A
- Revenue This Year
- ACRS N/A
- ACHV N/A
- Revenue Next Year
- ACRS N/A
- ACHV N/A
- P/E Ratio
- ACRS N/A
- ACHV N/A
- Revenue Growth
- ACRS 26.35
- ACHV N/A
- 52 Week Low
- ACRS $0.95
- ACHV $2.87
- 52 Week High
- ACRS $5.17
- ACHV $5.59
- Technical
- Relative Strength Index (RSI)
- ACRS 44.33
- ACHV 28.23
- Support Level
- ACRS $2.31
- ACHV $2.84
- Resistance Level
- ACRS $2.64
- ACHV $3.23
- Average True Range (ATR)
- ACRS 0.16
- ACHV 0.21
- MACD
- ACRS 0.02
- ACHV -0.04
- Stochastic Oscillator
- ACRS 58.76
- ACHV 6.86
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.